Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853513 | 1.00 | KDM4E (0.51) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| Aspartic Acid SCHEMBL10590014 | 0.86 | KDM4E (0.47) | KDM4ECYP2D6MAPK1SLC1A3SLC1A2 | |
| Aspartic Acid SCHEMBL10590016 | 0.86 | KDM4E (0.47) | KDM4ECYP2D6MAPK1SLC1A3SLC1A2 | |
| SCHEMBL6534817 | 0.84 | KDM4E (0.46) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| SCHEMBL1144618 | 0.83 | GBA1 (0.48) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| SCHEMBL6815589 | 0.83 | GBA1 (0.48) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| SCHEMBL757056 | 0.83 | GBA1 (0.53) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| D-Alanine SCHEMBL3725637 | 0.83 | SLC1A3 (0.51) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| Alanine SCHEMBL3254315 | 0.83 | SLC1A3 (0.51) | KDM4EGBA1CYP2D6MAPK1SLC1A3 | |
| Alanine SCHEMBL723059 | 0.83 | SLC1A3 (0.51) | KDM4EGBA1CYP2D6MAPK1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | claimed |
| EP-1386901-B1 | Method for producing an optically active beta-amino acid | TAKASAGO PERFUMERY CO LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | MATSUMURA KAZUHIKO | 2006-06-08 | — | — | US | disclosed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | AADAT, DAO, BCAT2 | KDM4E 4722/4885GBA1 561/4885CYP2D6 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.